Gwyneth Paltrow of Goop took the stage at Venture Houston to discuss investing and entrepreneurship. Photo courtesy of HX Venture Fund

If you're a startup founder, you might have some things in common with movie star-turned-entrepreneur Gwyneth Paltrow, who took the stage at Venture Houston this week.

Paltrow was joined with her investor Dana Settle of Greycroft in conversation with Melinda Spaulding of Texas Southern University as moderator. The duo discussed everything from their working relationship to the opportunities they see here in Houston.

Recognizing that, at the time, her decision to start a company was a bit confusing, Paltrow explained on the panel why she felt drawn to business and entrepreneurship. She described growing up in New York, idolizing her friends' parents on Wall Street, and she connected the dots between artistry and entrepreneurship for the audience.

"It struck me recently that the soul of an artist and the soul of an entrepreneur are actually very similar," she told the crowd. "When you're an artist you have this idea that you want to put out into the world and you think you're the only one that can do it — you have something specific and unique to add and you know you're going to do everything you can to put it into the world and to have success.

"And so you have to have this like abject, ridiculous self belief and you have to persevere through everything," she continued. "All of those qualities are exactly what you need to have as an entrepreneur."

The big difference between being an actor and an entrepreneur , Paltrow added, actors have to wait for someone to give them a job — they can't execute unless they get the part.

"I loved migrating over to being an entrepreneur," she said. "I had very strong feelings and instincts and a passion to connect people to great stuff and information — and I could do it on my own terms. I could do it on my own timeline, and nobody was barring or impeding the execution of those things."

Making the transition into entrepreneurship in such a public way came with its own unique set of challenges for Paltrow. While getting in front of venture capital investors wasn't a challenge, getting them to take her seriously was, she said, not even just because of her fame. The people in the room couldn't understand her company.

"The companies that are doing things for women, investors are having a hard time understanding them. I think that's true through and through," she said. "And it was certainly true when I went to go raise money. Everybody took the meetings, I think to get a selfie for their wife. ... And then they'd be like, 'no, thank you.'"

Greycroft — specifically with Settle — was an exception to the experience. Greycroft invested in Goop in 2019 and HX Venture Fund invested in Greycroft in 2020.

"Not everybody's for everybody. And finding the right investor for your company is so important," Settle said to the crowd. "I think getting those really trusted signals from other founders and other funders is the best way."

Since the event was hosted by HXVF and located in Houston, the topic shifted to the Bayou City and what Paltrow has observed of the ecosystem.

"Houston really has an opportunity to define who you all want to be as an investment community. And I think it's really exciting. You have such a massive influx of people coming here. I think you're set up to to support business in a way that, you know, unfortunately, we don't do in California — we make it a little tough," she said.

"I think it really becomes about articulating who what the community, what what do you want it to be? Who do you want to attract? It doesn't happen out of thin air. There has to be intention around how you articulate what the mission is in Houston for this community and start to talk about it and welcome those kinds of entrepreneurs and and define what you want it to be," she added.

Besides her relatable hatred of Excel, Paltrow shared part of her journey that founders from all backgrounds can identify with — identifying your own strengths and weaknesses.

"I have to be confident in where my strengths lie, and be able to index into those and know that I'm the expert in that domain," she said. "In the group dynamic where everyone brings their expertise to the table is really what makes it work.

"We have this thing as women where we have to do everything and it has to be perfect. It's impossible and it's not true," she continues. "Know your strengths, lean into them, don't be afraid to articulate what your strengths are not, and ask the questions you need to ask."

Settle agreed with Paltrow, adding "The best CEOs that I work with are the ones asking the right questions."

Goop Founder Gwyneth Paltrow and venture capitalists Dana Settle and Mitchell Green will headline Venture Houston next month. Images via venturehouston.com

Gwyneth Paltrow, VCs to headline exciting upcoming Houston summit

coming soon

A Houston-based fund of funds is bringing back its venture-focused event — and this year, you might recognize the keynote speaker.

Venture Houston hosted by the HX Venture Fund will take place on Monday, September 12, at The Ion. The day will kick off with a conversation with Goop founder and Academy Award-winning actress Gwyneth Paltrow in conversation with Dana Settle, co-founder and managing partner of New York-based Greycroft. Goop is among Greycroft's portfolio companies, and HXVF, which deploys capital in to out-of-town VCs they have an interest and intention in investing into Houston startups, invested in Greycroft in 2020.

Some of the event's other speakers — from outside Texas as well as home grown —include LeadEdge Capital's Mitchell Green, Cart.com's Omair Tariq, Solugen's Gaurab Chakrabati, and many more. The full event agenda and list of speakers are both available online.

The program of the event is centered around key topics directly affecting Houston's innovation ecosystem, such as energy transition, sustainability, startup scaling, the future of health care, entrepreneurship, talent acquisition, and more.

“Venture Houston will bring together some of the most proven venture capitalists from the nation to the Houston stage, alongside Houston’s corporate leaders and most innovative entrepreneurs," says Sandy Guitar, managing director of the HX Venture Fund. "We are delighted to bring conversations around lessons learned and best practices to The Ion so that we can continue to nurture the incredible growth we are experiencing in the innovation ecosystem in Houston.”

Venture Houston is supported and sponsored by organizations including Insperity, Rice University, Greater Houston Partnership, Silicon Valley Bank, and Halliburton Labs.

"Houston's innovation ecosystem is experiencing a compelling transformation," says Bob Harvey, president and CEO of the GHP. "Venture Houston 2022 is the premier event for corporate leaders, venture capital investors, and entrepreneurs to plug into what is happening in the city. We are proud to sponsor and share the stage with leaders helping to illuminate the power of venture capital for Houston’s innovation ecosystem."

Registration is open online for the September 12 event.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

New Houston biotech co. lands $30M for pulmonary fibrosis drug

drug money

Most of us can claim a scar or two on our bodies. But when scarring develops inside the body, it’s known as a fibrotic disorder. A freshly launched Houston company, Oorja Bio Inc., is working on a treatment that can help to repair cells and reduce the damage wrought by the growth of fibrotic tissue in patients.

Late last month, Oorja Bio hit the scene with a pair of big announcements. Not only has the company raised a $30 million Series A thanks to founding investor California-based Westlake BioPartners, but it has also already paved the way for a Phase 2 study to take place this year.

Oorja Bio received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), allowing the company to test its treatment in patients with idiopathic pulmonary fibrosis (IPF), a scarring of the lung tissue. IPF affects more than 150,000 adults in the United States and can result in a range of symptoms from shortness of breath to organ failure and death as it progresses.

Oorja Bio’s lead drug candidate, ORJ-001, was shown in a Phase 1 in-human trial to demonstrate “therapeutically relevant exposure and favorable tolerability” in 64 healthy adult volunteers in whom it was administered daily or weekly, according to a news release. Pre-clinical studies of ORJ-001 showed durable target tissue engagement and biomarker activity in bleomycin-induced lung fibrosis.

Administered subcutaneously, ORJ-001 is intended to improve and even restore function in cells that can reduce the signaling that causes IPF. It stops advancement of IPF and also allows for tissue repair. Currently available treatments for the disease can slow the development of IPF down, but do not address the declining lung function that’s inherent in its progression.

“The clinical and preclinical results from our studies to date give us confidence that ORJ-001 represents a novel treatment approach with the potential to repair and reverse fibrosis and modify disease progression in IPF,” Dr. Janethe Pena, CMO of Oorja Bio, said in the release.

“Our team is energized to deliver on our goal of redefining the future of fibrotic diseases, beginning with ORJ-001,” CEO and founder Sujay Kango added. “As we advance ORJ-001 in the clinic, we are embracing the paradigm shift in our biological understanding of IPF pathology that aligns with the central role of the alveolar epithelium. ORJ-001 was designed with this biology in mind and may provide, for the first time, a therapeutic intervention that repairs and reverses fibrosis and promotes disease modification.”

Most patients live only three to five years following their IPF diagnosis. Soon, ORJ-001 and Oorja Bio could give them a fighting chance.

Axiom Space tops $525M in oversubscribed round, announces Swiss subsidiary

funding boost

Axiom Space tacked on an additional $175 million to a previously announced capital raise, bringing the oversubscribed round to a total of more than $525 million.

Axiom shared in February that it had secured $350 million in a financing round led by Type One Ventures and Qatar Investment Authority. In the latest release from the company, Axiom reports that Japan-based MUFG Bank Ltd. joined the round as a new investor, in addition to continued participation from existing backers.

The funding will go toward developing the company's commercial space station, known as Axiom Station, and the production of its Axiom Extravehicular Mobility Unit (AxEMU) under its NASA spacesuit contract.

“Investor interest in this round outpaced what we set out to raise, which speaks to the moment we’re in,” Jonathan Cirtain, CEO and president of Axiom Space, said in the news release. “Our partners see what is possible in low-Earth orbit, and they see who is positioned to lead it.”

Axiom announced last month that it planned to open a Japanese subsidiary July 1. Earlier this week, it also shared plans to establish Axiom Space Switzerland, a wholly owned subsidiary based in Lucerne that is also expected to begin operations this summer.

The Switzerland subsidiary aims to establish Axiom's presence in Europe and help it partner with the European Space Agency and other space organizations and companies on the continent.

“Europe is a founding leader in the creation of the commercial space economy, and Switzerland is uniquely positioned to convene the government agencies, research institutions, and industrial entities that will shape its next decade,” Cirtain added in a separate release. “Axiom Space Switzerland facilitates the scaling of development and deployment of the infrastructure that will succeed the International Space Station.”

Texas cashes in among 10 best U.S. state economies in 2026 report

State Economics

A new study gauging the success or decline in economic performance in every state has revealed Texas' economy remains stable in 2026 after it dropped out of the top five to No. 8 last year.

Texas boasts the No. 8 best state economy in the U.S. this year, according to WalletHub's annual "Best & Worst State Economies" report. The personal finance website's analysts ranked all 50 states and the District of Columbia across 28 relevant metrics to measure each state's economic activity and health status, and its "innovation potential."

Notably, Texas leads the nation for the most exports per capita in the U.S. in a five-way tie with Louisiana, Kentucky, North Dakota, and Indiana. Across the study's three main categories, Texas ranked highly for its economic activity (No. 7) and economic health (No. 11), and the state's "innovation potential" rank is the 24th best in the nation.

This is how WalletHub ranked Texas' economic performance, where No. 1 is considered the best and No. 25 is considered average:
  • No. 6 – Change in non-farm payrolls
  • No. 8 – Change in GDP
  • No. 8 – Startup activity
  • No. 11 – Annual median household income
  • No. 18 – Government surplus/deficit per capita
  • No. 21 – Percentage of jobs in high-tech industries
  • No. 30 – Unemployment rate
WalletHub previously ranked Texas one of the top three states to start a business in 2026, with Houston earning its own entrepreneurial acclaim in separate rankings of the best big cities for new businesses and for starting a career.

"U.S. economic growth depends heavily on the performance of individual states, and some contribute more than others," the report's author wrote. "For example, California, Texas, New York and Florida have economies so large that if they were countries, they would rank in the top 20 in the world."

The five states with the worst state economies in 2026 are Rhode Island (No. 47), Maine (No. 48), Louisana (No. 49), Kentucky (No. 50), and West Virginia (No. 51).

The top 10 best state economies for 2026 are:

  • No. 1 – Massachusetts
  • No. 2 – Washington
  • No. 3 – Utah
  • No. 4 – California
  • No. 5 – Delaware
  • No. 6 – North Carolina
  • No. 7 – New York
  • No. 8 – Texas
  • No. 9 – Colorado
  • No. 10 – Florida

---

This article originally appeared on CultureMap.com.